The global artificial insemination market size was worth USD 2.27 billion in 2023. This value is further estimated to grow at a CAGR of 9.02% from 2024 to 2029 and reach USD 3.81 billion by 2029 from USD 2.47 billion in 2024.
The popularity and adoption of artificial insemination are growing significantly across the world. In this procedure, the sperm will be introduced directly into the reproductive tract. Artificial insemination is an effective way to treat infertility. There are various alternative insemination methods available, and some of them are Intrauterine Insemination (IUI), Intracervical Insemination (ICI), and Intratubal Insemination (ITI). Artificial insemination's success depends on the female's age, the cause associated with infertility, and the type of method used for the conception. The adoption of artificial insemination is expected to grow further in the coming years as it is less expensive and less invasive than other alternative options, such as IVF.
The incidence of infertility among couples and individuals is growing significantly worldwide. For instance, according to the data published by the National Institute of Health (NIH), 9% of men and 11% of women of reproductive age suffered from fertility issues in the recent past in the United States. As per World Health Organization (WHO), an estimated 48 million couples and 180 million individuals have infertility issues worldwide. Several treatment procedures are available to treat infertility, such as artificial insemination, IVF, and others. Couples and individuals can increase their chances of conception by leveraging the treatment procedures. Artificial insemination is primarily used for couples who are with issues of infertility. Changes in lifestyles, increasing stress, and frequent environmental exposure are believed to result in infertility among people. In the near future, more couples and individuals are expected to face issues with infertility, which is expected to result in the growing demand for assisted reproductive technologies and treatments, including artificial insemination.
People's awareness of various reproductive treatments has spiked recently. Various assisted reproductive technologies, including artificial insemination, are available via various media channels. This growing awareness has led to the increasing acceptance of these technologies and the growing number of artificial insemination procedures. In addition, the presence of an increasing number of infertility clinics and hospitals has helped promote awareness regarding artificial insemination and increased the accessibility of these treatments to the needy.
In addition, growing support from the governments of some countries for same-sex marriages and the inclusion of fertility treatment costs in insurance coverage in some countries are expected to fuel the market's growth rate. Women who are engaged in their full-time professional careers are willing to get conceived at later ages, which sometimes creates complexities in the conception. Such couples are apt for assisted reproductive treatments such as artificial insemination to fight infertility. The increasing choice of planned parenthood among working women is expected to result in the growing demand for artificial insemination. Furthermore, the growing adoption of technological developments in artificial insemination, increasing disposable income, and the rising number of infertility clinics and hospitals worldwide are estimated to boost the artificial insemination market growth during the forecast period.
Due to these higher costs, the accessibility to these treatments is not possible for a large population, which results in reduced demand for these treatment options. In addition, ethical and religious concerns associated with artificial insemination in some geographies worldwide are anticipated to affect market growth negatively. Furthermore, poor awareness levels among people in some countries regarding assisted reproductive technologies are estimated to inhibit the market's growth rate. Furthermore, limited insurance coverage and a stringent regulatory environment are predicted to impact the artificial insemination market growth negatively.
REPORT METRIC |
DETAILS |
Market Size Available |
2024 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Type, Source Type, End-User, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Key Market Players |
Rocket Medical, INVO Bioscience, Vitrolife, Pride Angel, Genea Limited, MedGyn Products, Inc., Rinovum Women's Health, Conceivex Inc., Tenderneeds Fertility, Hi-Tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation |
The intrauterine insemination segment accounted for the largest share of the global artificial insemination market in 2023 and segmental growth is expected to dominate the market during the forecast period. Among all the available treatment options, intrauterine insemination has the highest pregnancy success rate and is one of the most popular options. In addition, intrauterine insemination is a non-invasive procedure, and the adoption is high. Furthermore, the growing rate of infertility, increasing adoption of technological advancements to further enhance the quality of IUI procedures, and growing awareness among people regarding assisted reproductive technologies are anticipated to help the IUI segment to register the fastest CAGR during the forecast period.
On the other hand, the intravaginal segment captured the second-largest share of the global artificial insemination market in 2023 and is predicted to grow at a healthy CAGR during the forecast period. In addition, surrogacy and donor insemination can benefit from IVI, which can be done at a fertility clinic or home.
The artificial insemination by husband (AIH) segment is anticipated to hold a major share of the global market during the forecast period and showcase the fastest CAGR. In this procedure, the semen from the husband will be collected to do the artificial insemination. This is the most preferred way of doing artificial insemination worldwide as this enables the couple to have some biological connection and eliminates the need for sperm donors. The segment's growth can be attributed to the rapid adoption of technological developments in artificial insemination procedures, changes in regulations, and changing consumer preferences.
However, the artificial insemination by donor (AID) segment is anticipated to witness a healthy CAGR in the coming years owing to the increasing adoption by single women and same-sex couples.
The fertility centers segment had the largest share in the global artificial insemination market in 2022 and is anticipated to grow rapidly over the forecast period. The segment's growth rate is primarily driven by the growing fertility rates worldwide. In addition, the number of medical institutes offering infertility treatment has spiked in recent years. As a result, fertility clinics can undertake all artificial insemination techniques.
Because of advanced technology, government backing for fertility insurance, and increased awareness of the treatment option for infertility, the North American market accounted for a significant share of the global market in 2022. In addition, infertility treatment procedures such as artificial insemination and hormone therapy to boost egg production, known as assisted reproductive technology, are driving regional market expansion.
Europe captured a substantial share of the worldwide market in 2023 and is expected to register a promising CAGR during the forecast period. The growth of the European market is majorly driven by the growing number of couples having issues with fertility. According to the data published by the European Society of Human Reproduction and Embryology, an estimated 25 million people in Europe suffered from infertility in 2021. In addition, factors such as the increasing need for assisted reproductive technologies and rising demand for non-invasive and minimally invasive fertility treatments are propelling the artificial insemination market growth in Europe. To address the growing demand for artificial insemination, the key market participants of Europe are investing considerable amounts in R&D to bring new medical devices and services.
The Asia-Pacific region is anticipated to showcase the fastest CAGR worldwide during the forecast period. The growing rate of infertility in APAC countries such as India and China is majorly driving the APAC market growth. In addition, the market growth of the APAC region is anticipated to be driven by the growing disposable income in developing countries. Furthermore, in recent years, the awareness among the APAC population regarding the availability of various assisted reproductive technologies and treatments has grown significantly, one of the key factors propelling the regional market growth. In addition, consistent improvements in the healthcare systems of APAC countries and growing support from various governments of APAC countries for ART are expected to boost the growth rate of the APAC market during the forecast period.
The Latin American region is forecasted to showcase a CAGR of 9.94% from 2024 to 2029.
Rocket Medical, INVO Bioscience, Vitrolife, Pride Angel, Genea Limited, MedGyn Products, Inc., Rinovum Women's Health, Conceivex Inc., Tenderneeds Fertility, Hi-Tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation are a few of the leading companies operating in the global artificial insemination market and profiled in this report.
By Type
By Source
By End-User
By Region
Frequently Asked Questions
The global artificial insemination market size is estimated to be worth USD 3.81 billion by 2029 and was valued at USD 2.47 billion in 2024
.
The intrauterine segment is predicted to showcase dominance in the global artificial insemination market from 2024 to 2029.
The North American region accounted for the majority of the share in the global artificial insemination market in 2023.
Rocket Medical, INVO Bioscience, Vitrolife, Pride Angel, Genea Limited, MedGyn Products, Inc., Rinovum Women's Health, Conceivex Inc., Tenderneeds Fertility, Hi-Tech Solutions, Fujifilm Irvine Scientific, and Kitazato Corporation are some of the major companies operating in the artificial insemination market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region